Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

13 Sökresultat.
Relevans Bedömning Nya först Gamla först

Screening Serology GOAL Trial B-cell Lymphoma NCT02499003

- 2021-09-20 - 1 Formulär, 1 Item-grupp, 8 Dataelement, 1 Språk
Item-grupp: Serology Viral
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Visit: Screening. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results - Hematology Weeks 4, 5 and 6

- 2018-07-25 - 1 Formulär, 2 Item-grupper, 7 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology finding
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Follow-UP

- 2018-07-25 - 1 Formulär, 3 Item-grupper, 32 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Week 7

- 2018-07-25 - 1 Formulär, 3 Item-grupper, 28 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Week 13

- 2018-07-25 - 1 Formulär, 3 Item-grupper, 28 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Week 3

- 2018-07-25 - 1 Formulär, 3 Item-grupper, 28 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results - Baseline

- 2018-07-13 - 1 Formulär, 5 Item-grupper, 37 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology finding, Chemistry, Pregnancy Test, Beta-2 Microglobulin (Serum)
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Reference Ranges

- 2018-07-10 - 1 Formulär, 5 Item-grupper, 15 Dataelement, 1 Språk
Item-grupper: Administrative Data, Hematology, Other Parameters, Chemistry, Thyroid Parameters
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Complete this form for each clinical lab for which data are reported on case report forms. For data reported from outside institutions, please obtain the reference ranges and lab certification documentation. Use same Lab ID number on all laboratory forms. The form only needs to be completed once for each lab unless ranges or units change.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Identification Log

- 2018-07-10 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Laboratory Identification
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Laboratory GOAL Trial B-cell Lymphoma NCT02499003

- 2018-01-04 - 1 Formulär, 3 Item-grupper, 123 Dataelement, 1 Språk
Item-grupper: Admininstrative data, Laboratory Hematology, Laboratory Blood chemistry
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Pregnancy test GOAL Trial B-cell Lymphoma NCT02499003

- 2018-01-04 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Pregnancy Test
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Laboratory GOAL Trial B-cell Lymphoma NCT02499003

- 2018-01-01 - 1 Formulär, 4 Item-grupper, 150 Dataelement, 1 Språk
Item-grupper: Admininstrative data, Laboratory Hematology, Laboratory Blood chemistry, Laboratory Parameters
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial